Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapies for high unmet medical needs. Its commercial portfolio includes HETLIOZ for non-24-hour sleep-wake disorder and sleep disturbances in Smith-Magenis syndrome, Fanapt for bipolar I disorder and schizophrenia, and PONVORY for inflammatory/autoimmune disorders like ulcerative colitis and psoriasis. The company also has several drugs in development, including Tradipitant, VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A, and Type 2S (CMT2S). The VNDA YTD return is shown above.
The YTD Return on the VNDA YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether VNDA YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the VNDA YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|